Anti-ccr5 antibody
CA 2476901 C · Owner: Pdl Biopharma, Inc. · Inventors: Olson, William C.; Maddon, Paul J.; Tsurushita, Naoya
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097) and (ii) two , heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVgl:HuPR0140 (mutB+D+I)-VH (ATCC Deposit Designation PTA- 4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 21, 2003 and granted October 9, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 21, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 21, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.